908 Devices MASS 深 沪
交易中 10-15 12:07:24 美东时间
11.88
+0.050
+0.42%
华盛通- 最 高11.95
- 今 开11.55
- 成交量 10.70万股
- 最 低 11.52
- 昨 收 11.83
- 总市值 4.91亿
- 52周最高 13.348
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 5.025
- 委 比 -87.31%
- 总股本 4133.37万
- 历史最高 79.60
- 量 比 0.89
- 振 幅 3.63%
- 历史最低 1.81
- 每 手 1
- 风险率 1.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
Canaccord Genuity Initiates Coverage On 908 Devices with Buy Rating, Announces Price Target of $13.5
Canaccord Genuity analyst Austin Moeller initiates coverage on 908 Devices (NASDAQ:MASS) with a Buy rating and announces Price Target of $13.5.
09-10 20:09
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
908 Devices shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance.
908 Devices shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance.
08-12 01:09
908 Devices Raises FY2026 Sales Guidance from $67.000M-$70.000M to $68.000M-$70.000M vs $68.585M Est
908 Devices (NASDAQ:MASS) raises FY2026 sales outlook from $67.000 million-$70.000 million to $68.000 million-$70.000 million vs $68.585 million estimate.
08-11 19:03
908 Devices Q2 EPS $(0.32) Misses $(0.17) Estimate, Sales $16.074M Beat $15.374M Estimate
908 Devices (NASDAQ:MASS) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.17) by 88.24 percent. This is a 11.11 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $16.074 million ...
08-11 19:03
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Roth Capital Initiates Coverage On 908 Devices with Buy Rating, Announces Price Target of $11
Roth Capital analyst Max Masucci initiates coverage on 908 Devices (NASDAQ:MASS) with a Buy rating and announces Price Target of $11.
07-29 19:04
908 Devices将出席Canaccord Genuity第46届年度增长大会
手持式化学分析仪器制造商908 Devices Inc．宣布，公司管理层将出席即将举行的Canaccord Genuity第46届年度增长大会，并发表演讲...
07-28 21:01
Shares of electronic equipment, instruments and components stocks are trading lower amid overall market weakness as stronger-than-expected U.S. payroll growth in May erodes confidence in a Fed rate cut.
Shares of electronic equipment, instruments and components stocks are trading l...
06-06 03:11
